EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. / Fokkens, W. J.; Viskens, An Sofie; Backer, Vibeke; Conti, Diego; de Corso, Eugenio; Gevaert, Philippe; Scadding, Glenis K.; Wagemann, Martin; Sprekelsen, Manuel Bernal; Chaker, Adam; Heffler, Enrico; Han, Joseph K.; Staeyen, Elizabeth Van; Hopkins, Claire; Mullol, Joaquim; Peters, Anju; Reitsma, Sietze; Senior, Brent A.; Hellings, Peter W.

I: Rhinology, Bind 61, Nr. 3, 2023, s. 194-202.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Fokkens, WJ, Viskens, AS, Backer, V, Conti, D, de Corso, E, Gevaert, P, Scadding, GK, Wagemann, M, Sprekelsen, MB, Chaker, A, Heffler, E, Han, JK, Staeyen, EV, Hopkins, C, Mullol, J, Peters, A, Reitsma, S, Senior, BA & Hellings, PW 2023, 'EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023', Rhinology, bind 61, nr. 3, s. 194-202. https://doi.org/10.4193/Rhin22.489

APA

Fokkens, W. J., Viskens, A. S., Backer, V., Conti, D., de Corso, E., Gevaert, P., Scadding, G. K., Wagemann, M., Sprekelsen, M. B., Chaker, A., Heffler, E., Han, J. K., Staeyen, E. V., Hopkins, C., Mullol, J., Peters, A., Reitsma, S., Senior, B. A., & Hellings, P. W. (2023). EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology, 61(3), 194-202. https://doi.org/10.4193/Rhin22.489

Vancouver

Fokkens WJ, Viskens AS, Backer V, Conti D, de Corso E, Gevaert P o.a. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61(3):194-202. https://doi.org/10.4193/Rhin22.489

Author

Fokkens, W. J. ; Viskens, An Sofie ; Backer, Vibeke ; Conti, Diego ; de Corso, Eugenio ; Gevaert, Philippe ; Scadding, Glenis K. ; Wagemann, Martin ; Sprekelsen, Manuel Bernal ; Chaker, Adam ; Heffler, Enrico ; Han, Joseph K. ; Staeyen, Elizabeth Van ; Hopkins, Claire ; Mullol, Joaquim ; Peters, Anju ; Reitsma, Sietze ; Senior, Brent A. ; Hellings, Peter W. / EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. I: Rhinology. 2023 ; Bind 61, Nr. 3. s. 194-202.

Bibtex

@article{9f1e2135c2114ad88cbe2f335e93fd0b,

title = "EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023",

abstract = "Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.",

keywords = "biologics, biomarkers, Chronic rhinosinusitis, indication, nasal polyps, patient selection, thera-peutic response, type 2 inflammation",

author = "Fokkens, {W. J.} and Viskens, {An Sofie} and Vibeke Backer and Diego Conti and {de Corso}, Eugenio and Philippe Gevaert and Scadding, {Glenis K.} and Martin Wagemann and Sprekelsen, {Manuel Bernal} and Adam Chaker and Enrico Heffler and Han, {Joseph K.} and Staeyen, {Elizabeth Van} and Claire Hopkins and Joaquim Mullol and Anju Peters and Sietze Reitsma and Senior, {Brent A.} and Hellings, {Peter W.}",

year = "2023",

doi = "10.4193/Rhin22.489",

language = "English",

volume = "61",

pages = "194--202",

journal = "Rhinology. Supplement",

issn = "1013-0047",

publisher = "International Rhinologic Society",

number = "3",

}

RIS

TY - JOUR

T1 - EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023

AU - Fokkens, W. J.

AU - Viskens, An Sofie

AU - Backer, Vibeke

AU - Conti, Diego

AU - de Corso, Eugenio

AU - Gevaert, Philippe

AU - Scadding, Glenis K.

AU - Wagemann, Martin

AU - Sprekelsen, Manuel Bernal

AU - Chaker, Adam

AU - Heffler, Enrico

AU - Han, Joseph K.

AU - Staeyen, Elizabeth Van

AU - Hopkins, Claire

AU - Mullol, Joaquim

AU - Peters, Anju

AU - Reitsma, Sietze

AU - Senior, Brent A.

AU - Hellings, Peter W.

PY - 2023

Y1 - 2023

N2 - Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.

AB - Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.

KW - biologics

KW - biomarkers

KW - Chronic rhinosinusitis

KW - indication

KW - nasal polyps

KW - patient selection

KW - thera-peutic response

KW - type 2 inflammation

U2 - 10.4193/Rhin22.489

DO - 10.4193/Rhin22.489

M3 - Journal article

C2 - 36999780

AN - SCOPUS:85162822635

VL - 61

SP - 194

EP - 202

JO - Rhinology. Supplement

JF - Rhinology. Supplement

SN - 1013-0047

IS - 3

ER -

ID: 366543104